237 related articles for article (PubMed ID: 32416408)
1. As a potential treatment of COVID-19: Montelukast.
Fidan C; Aydoğdu A
Med Hypotheses; 2020 Sep; 142():109828. PubMed ID: 32416408
[TBL] [Abstract][Full Text] [Related]
2. The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast.
Almerie MQ; Kerrigan DD
Med Hypotheses; 2020 Oct; 143():109883. PubMed ID: 32492562
[TBL] [Abstract][Full Text] [Related]
3. Possible Therapeutic Potential of Cysteinyl Leukotriene Receptor Antagonist Montelukast in Treatment of SARS-CoV-2-Induced COVID-19.
Dey M; Singh RK
Pharmacology; 2021; 106(9-10):469-476. PubMed ID: 34350893
[TBL] [Abstract][Full Text] [Related]
4. Leukotrienes, a potential target for Covid-19.
Citron F; Perelli L; Deem AK; Genovese G; Viale A
Prostaglandins Leukot Essent Fatty Acids; 2020 Oct; 161():102174. PubMed ID: 32977289
[No Abstract] [Full Text] [Related]
5. Montelukast drug activity and potential against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Copertino DC; Duarte RRR; Powell TR; de Mulder Rougvie M; Nixon DF
J Med Virol; 2021 Jan; 93(1):187-189. PubMed ID: 32658304
[No Abstract] [Full Text] [Related]
6. COVID-19, severe asthma, and biologics.
García-Moguel I; Díaz Campos R; Alonso Charterina S; Fernández Rodríguez C; Fernández Crespo J
Ann Allergy Asthma Immunol; 2020 Sep; 125(3):357-359.e1. PubMed ID: 32553608
[No Abstract] [Full Text] [Related]
7. Clinical course of asthma in 4 cases of coronavirus disease 2019 infection.
Codispoti CD; Bandi S; Patel P; Mahdavinia M
Ann Allergy Asthma Immunol; 2020 Aug; 125(2):208-210. PubMed ID: 32437838
[No Abstract] [Full Text] [Related]
8. Montelukast and Coronavirus Disease 2019: A Scoping Review.
Sharifinejad N; Sharafian S; Salekmoghadam S; Tavakol M; Qorbani M
Iran J Allergy Asthma Immunol; 2021 Aug; 20(4):384-393. PubMed ID: 34418892
[TBL] [Abstract][Full Text] [Related]
9. Role of leukotriene pathway and montelukast in pulmonary and extrapulmonary manifestations of Covid-19: The enigmatic entity.
Al-Kuraishy HM; Al-Gareeb AI; Almulaiky YQ; Cruz-Martins N; El-Saber Batiha G
Eur J Pharmacol; 2021 Aug; 904():174196. PubMed ID: 34004207
[TBL] [Abstract][Full Text] [Related]
10. Targeting inflammation and cytokine storm in COVID-19.
Huang Q; Wu X; Zheng X; Luo S; Xu S; Weng J
Pharmacol Res; 2020 Sep; 159():105051. PubMed ID: 32603772
[No Abstract] [Full Text] [Related]
11. [Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?].
Nisole S; Saulnier A; Gatignol A
Virologie (Montrouge); 2020 Jun; 24(3):135-141. PubMed ID: 32648548
[No Abstract] [Full Text] [Related]
12. Can Colchicine as an Old Anti-Inflammatory Agent Be Effective in COVID-19?
Nasiripour S; Zamani F; Farasatinasab M
J Clin Pharmacol; 2020 Jul; 60(7):828-829. PubMed ID: 32445400
[No Abstract] [Full Text] [Related]
13. Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson's Disease.
Wallin J; Svenningsson P
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070609
[TBL] [Abstract][Full Text] [Related]
14. Montelukast alleviates inflammation in experimental autoimmune encephalomyelitis by altering Th17 differentiation in a mouse model.
Han B; Zhang YY; Ye ZQ; Xiao Y; Rasouli J; Wu WC; Ye SM; Guo XY; Zhu L; Rostami A; Wang LB; Zhang Y; Li X
Immunology; 2021 Jun; 163(2):185-200. PubMed ID: 33480040
[TBL] [Abstract][Full Text] [Related]
15. Montelukast, a Cysteinyl Leukotriene Receptor 1 Antagonist, Induces M2 Macrophage Polarization and Inhibits Murine Aortic Aneurysm Formation.
Kawai Y; Narita Y; Yamawaki-Ogata A; Usui A; Komori K
Biomed Res Int; 2019; 2019():9104680. PubMed ID: 31263710
[TBL] [Abstract][Full Text] [Related]
16. Dexamethasone: A boon for critically ill COVID-19 patients?
Patel SK; Saikumar G; Rana J; Dhama J; Yatoo MI; Tiwari R; Rodríguez-Morales AJ; Dhama K
Travel Med Infect Dis; 2020; 37():101844. PubMed ID: 32791213
[No Abstract] [Full Text] [Related]
17. Acute inflammation and pathogenesis of SARS-CoV-2 infection: Cannabidiol as a potential anti-inflammatory treatment?
Costiniuk CT; Jenabian MA
Cytokine Growth Factor Rev; 2020 Jun; 53():63-65. PubMed ID: 32467020
[No Abstract] [Full Text] [Related]
18. Why not consider an endothelin receptor antagonist against SARS-CoV-2?
Javor S; Salsano A
Med Hypotheses; 2020 Aug; 141():109792. PubMed ID: 32361169
[No Abstract] [Full Text] [Related]
19. Taming the cytokine storm: repurposing montelukast for the attenuation and prophylaxis of severe COVID-19 symptoms.
Sanghai N; Tranmer GK
Drug Discov Today; 2020 Dec; 25(12):2076-2079. PubMed ID: 32949526
[TBL] [Abstract][Full Text] [Related]
20. Montelukast: more than a cysteinyl leukotriene receptor antagonist?
Tintinger GR; Feldman C; Theron AJ; Anderson R
ScientificWorldJournal; 2010 Dec; 10():2403-13. PubMed ID: 21170491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
